Abstract Transcranial near-infrared laser therapy (TLT) improves behavioral outcome in animal stroke models when applied as single treatment within the 24 h of the stroke onset. It is unknown if the multiple TLT treatments have an added beneficial effect. We aim to determine whether multiple irradiations with TLT would have further improvement in behavioral outcomes in the rabbit small clot embolic stroke model (RSCEM). Using the RSCEM, two and three TLT treatments (7.5-20 mW/cm 2 ) were compared against single laser treatment alone (7.5-10.8 mW/cm 2 ). Two sham irradiation groups were added for the control curves. The double treatment group received TLT at 3 and 5 h and the triple treatment group at 2, 3, and 4 h after embolization. Behavioral analysis was conducted 24 h after embolization using a dichotomized behavioral score. The determination of the effective clot amount (milligrams) that produces neurological deficits in 50 % of the rabbits (P 50 ) was used to compare TLT treatments with the sham. The P 50 for double treatment was 5.47 ± 0.90, with n 039; the corresponding P 50 value for a single treatment was 3.87± 0.73, with n038; and the corresponding control curve was 3.25±0.4, n032. The P 50 for triple treatment was 5.91± 0.49, with n023; the corresponding P 50 value for a single treatment was 3.09±0.59, with n015, and the corresponding control curve was 1.71 ± 0.26, with n 017. The triple treatment had 91 % improvement when compared with the single treatment and 245 % improvement when compared with the sham. The present study suggests that the additional TLT treatments provide further behavioral improvement when given during the acute ischemic stroke phase.
Introduction
Low-level laser therapy (LLLT) uses low-powered laser light, at wavelengths from approximately 600-1,100 nm to induce a photochemical reaction in the cell, without generating heat, by a process referred to as biostimulation or photobiomodulation [1] . Transcranial infrared laser therapy (TLT) is a form of LLLT that is able to penetrate the skull at full strength and is capable to photostimulate the brain tissue located a few centimeters below the skull [2] .
The effects of TLT in acute ischemic stroke have been widely studied. Lapchak et al. used the rabbit small clot embolic stroke model (RSCEM) to demonstrate long-term behavioral improvement with TLT when treating animals at 3 and 6 h after embolization [3] . Using the middle cerebral artery occlusion (MCAO) rat model, Oron et al. demonstrated that TLT applied at 24 h after the ischemic injury produced a significant improvement of the neurological severity score as compared with the controls when measured 14 days after the stroke [4] . Detaboada et al. replicated these results in the same rat MCAO model [5] . Likewise, human studies have showed safety and favorable effects when TLT is applied as a single treatment within 24 h of the stroke onset [6, 7] . The NeuroThera Effectiveness and Safety Trials (NEST) 1 and 2 demonstrated safety for human treatment in acute ischemic stroke [6, 7] , and the pooled analysis of both trials showed efficacy of TLT treatment for reduction in long-term disability measured by the modified Rankin Scale [8] .
The different treatment times, irradiation doses, and energy levels of TLT tested in acute ischemic stroke models have been frequently successful in reaching good outcomes [3-6, 9, 10] . However, the optimal timing and the irradiation dose for acute ischemic stroke have not yet been established. Some studies have shown an incremental benefit of LLLT with higher irradiation power and energy levels. But applying additional LLLT energy can have minimal or no effect on the target tissue due to the biphasic response of LLLT [11] . Further irradiation can even be detrimental to the tissue itself due to its thermal effect [12] .
Most of the neuroprotective therapies tested in animals have shown better efficacy when used early in the ischemic injury process, but eventually losing their efficacy as time from onset to initiation of therapy increases [13] . In contrast TLT appears to be equally effective when applied at different times within the first 24 h of the ischemic brain injury. It is possible, therefore, that TLT has the potential to photomodulate at different stages of the brain ischemic cascade. We postulate that the multiple treatments of TLT during the acute ischemia will act synergically, enhancing furthermore the behavioral outcome. The purpose for this study was to determine whether the second and third irradiation treatment with TLT during the ischemic phase of the stroke would result in additional improvement of the behavioral outcomes using the RSCEM.
Methods
All the animal procedures used in this study were approved by the Department of Veterans Affairs and the Veterans Administration San Diego Healthcare System and met the guidelines of the National Institutes of Health. Male New Zealand white rabbits (Western Oregon Rabbit Co. Philomath, OR, USA) weighing 2 to 2.5 kg were used for the experiments.
All surgical procedures and microemboli preparation were done as described previously [14] . Briefly, rabbits were anesthetized with isoflurane through a facemask at 5 % in 3 L/min during induction and 3 % in 3 L/min as a maintenance dose. The right internal carotid artery was exposed, and the external carotid artery and the common carotid artery were ligated. The additional branches which are seen originating from the internal carotid artery were also ligated. A catheter oriented towards the brain was inserted into the common carotid and secured with ligatures. The incision was closed around the catheter, and the catheter was filled with heparinized saline and plugged with injection caps. The animals were allowed to recover from anesthesia for at least 2 h before embolization. Microemboli were prepared from blood drawn from a donor rabbit and allowed to clot at 37°C for 3.5 h. The clot was suspended in Dulbecco's PBS solution containing 0.1 % bovine serum albumin and fragmented with a polytron. The clot fragments were sized by sequential filtration through 240 μm 2 screen and 100 μm 2 nylon net. The clots retained by the nylon net were washed, suspended again in PBS, and allowed to settle. The supernatant was then removed and the particles were mixed with tracer quantities of 15 μm radio-labeled microspheres. An aliquot of particles was then removed for the determination of specific activity. The appropriate volumes of PBS solution were then added to the particles so that a predetermined weight of particles was suspended in 1 mL, and these suspended particles were drawn into a syringe. The clot particles were rapidly injected through the carotid catheter and then flushed with 3 mL of normal saline. After the embolization process was completed, the catheter was ligated close to the neck, and the remaining exposed catheter and injection ports were cut off. Before returning the animals to the cages, they were observed continuously for a minimum of 1 h after the treatments. The surviving animals were euthanized 24 h post embolization with 1 to 1.5 mL of Beuthanasia-D through the marginal ear vein.
Transcranial laser therapy and treatment allocation
The rabbits were randomly allocated into treatment groups before embolization, with concealment of the randomization sequence until all behavioral and postmortem analyses were complete. For the TLT treatments, rabbits were placed in a Plexiglas restrainer for the duration of the treatment, and the laser probe was placed in direct contact with the skin overlying the skull. An AcuLaser low-energy laser, with wavelength of 808.5 nm and fitted with an OZ Optics Ltd fiber optic cable and with laser probe measuring 2 cm in diameter, was used.
To assess the effect of multiple doses of TLT treatment during the acute ischemia, two sets of experiments were planned using the RSCEM. The first group of rabbits was randomized to double TLT treatment with a power dose of 7.5 mW/cm 2 given at 3 and 5 h or a single TLT given at 3 h. After the completion of the first group of experiments with the double laser treatment, we adjusted the settings for the triple laser dose experiments by increasing the power and narrowing the treatment times. In this second group, the animals were randomly assigned with triple TLT treatments at 2, 3, and 4 h post embolization or single TLT at 2 h post embolization. We used a power dose of 10.8 mW/cm 2 for the single therapy and 20 mW/cm 2 for the triple therapy group. The irradiation treatment duration was 2 min for each dose in all laser experiments. The independent control curves were obtained for each set of experiments, and behavioral analysis was conducted 24 h after embolization. The behavior of each animal was rated as either normal or abnormal/dead using a dichotomized behavioral score by an examiner blinded to the original treatment assignment. The behaviorally normal rabbits did not have any signs of impairment; whereas behaviorally abnormal rabbits had loss of balance, head leans, circling, seizure-type activity, or limb paralysis.
The total radioactivity in the brain was measured by placing small pieces of the dissected brain into a portable gamma counter, and the amount of radiolabel present in the brain was compared with that contained in the labeled blood clot before embolization. If fewer than 10 % of the total counts were found in the brain, it was assumed that the labeled blood clot had not reached the brain, and the animal was excluded from analyses.
Quantal response analysis
Briefly, to evaluate the quantitative relationship between the number of clots in the brain and neurological deficits, logistic S-shaped curves were fitted by a computer to the quantal dose-response data. These variables are measures of the amount in milligrams of the microclot that produce neurologic dysfunction in 50 % of animals in a group (P 50 ). A separate curve is generated for each TLT treatment group, and a statistically significant increase in the P 50 value compared with control is indicative of a behavioral improvement. The data were analyzed using the t test, which included the Bonferroni correction when appropriate.
Results
In the first randomized group of rabbits, the P 50 value for the sham at 5 h after embolization was 3.25±0.49 mg, with slope of 4.84±2.06 and n032. Rabbits that were treated 3 h post embolization with a single TLT had P 50 value of 3.87±0.73 mg, with slope of 2.13±0.89 and n038. The TLT double treatment, given at 3 and 5 h of the stroke onset, has significantly increased the P 50 by 69 % compared to the sham; the P 50 value was 5.47±0.90 mg, with slope of 3.76± 1.78 and n039. The double laser therapy had a nonsignificant increase of 41 % in animal behavior improvement when compared with the single laser treatment (Fig. 1) .
In the second randomized group of rabbits, the P 50 of the sham at 24 h after embolization was 1.71±0.26 mg, with slope of 5.02±3.13 and n017. The animals that were treated at 2 h post embolization with TLT had P 50 value of 3.09± 0.51, with slope of 4.83±2.74 and n015. Triple TLT treatment given at 2, 3, and 4 h post embolization has significantly increased the P 50 to 5.91±0.49, with slope of 9.46± 5.45 and n023, which was a 265 % improvement when compared with the sham and a 91 % improvement compared with the single treatment (Fig. 2) .
Discussion
Using the RSCEM, we found an effective enhancement of behavioral outcome with additional treatments of laser therapy during the acute brain ischemic phase. Such better outcome was coupled with the total laser energy dose applied to the animals. There was a 245 % behavioral improvement compared to the controls when the triple treatment was applied. Such beneficial incremental Fig. 1 Effect of laser treatment on stroke outcomes in rabbits (double laser curves). The P 50 value for normal control rabbits given at 3 h is 3.25±0.4 (black curve) and for the single laser is 3.87±0.73 (blue dotted curve). The double laser (green curve) significantly shifted the P 50 to 5.47±0.90, n039. P00.01 vs. controls Fig. 2 Effects of laser treatments on stroke outcomes in rabbits (triple laser curves). The P 50 value for normal control rabbits (shown as black curve, n017) is 1.71 ± 0.26 mg; single laser treatment (blue curve, n0 15) significantly shifted P 50 to 3.09 ± 0.51 mg, with P00.02 vs. control. Triple laser treatment (green curve, n023) further increased P 50 to 5.91 ± 0.49 mg, P00.01 vs. single treatment treatment response has not been observed with any neuroprotective agent tested on the RSCEM, including recombinant tissue plasminogen activator (t-PA) ( Table 1) . We noted during the experiments that some animals, which were embolized with very high clot weight, surprisingly survived. These animals are usually expected to die from clot burden a few hours after embolization, but when given a triple laser dose, they had a normal behavior 24 h after the embolization. In our experience, such treatment response using the RSCEM has only been observed after treatment with t-PA.
Although the neuroprotective effects of LLLT in acute brain ischemia are not fully understood, research progress in cellular and molecular biology has revealed some of its mechanism of actions. The LLLT is absorbed by the mitochondrial cytochrome c oxydase causing an upregulation of the cellular respiratory chain. A host of downstream cellular responses involving nitric oxide, reactive oxygen species, adenosine monophosphate, and an increase of ATP ensues, which ultimately might dictate the LLLT effects [1] .
Lapchak et al. using the same RSCEM have confirmed an increase of ATP production after TLT in the rabbit ischemic brain [9] . Such increase appears to be energy dosedependent [9] . However, LLLT studies have also showed a bell-shaped curve response to light therapy with detrimental effects at higher energies [1] . High-energy levels could initiate a bigger increase in ROS and a decrease in mitochondrial membrane potential, which can induce damage to the mitochondria and lead to toxicity [15] .
It seems plausible that the improvement of the rabbit behavioral outcome was not only due to the delivery of higher quantities of LLLT energy, but also by the photostimuation of different biological events during the ischemic cascade itself. In general the temporal profile of the main pathophysiological mechanism underlying the acute focal brain ischemia begins with cellular bioenergetic failure followed by excitotoxicity, oxidative stress, blood brain barrier dysfunction, and post ischemic inflammation [16] . The augmentation of ATP by LLLT not only provides a bioenergetic relief, but it can also modulate separate biological reactions.
Several other different mechanisms of LLLT photoactivation have been postulated. Under hypoxic conditions the cytochrome c oxidase reduces nitrite to nitric oxide (NO) [17] . Such reaction is also enhanced by LLLT, increasing the local production of NO [18] and improving the local cerebral blood flow in the brain ischemic tissue [19] . Other ischemic stroke animal models have shown that LLLT also decreases apoptosis [20] , leads to the production of endogenous neurotrophic factors, and enhances the recovery of function via neurogenesis [4, 21] .
Single TLT dose has shown an improvement of the outcomes in different animal models [3, 5] and in human clinical trials [6, 7] . Conversely, in our first set of experiments, despite the apparent incremental effect of the double treatment, single laser treatment was not significantly better than the sham. While there was a considerable variability in the outcome of the animals within similar clot weight, we believe that mainly the use lower power density of 7.5 mW/ cm 2 accounted for such results. After we observed that a double TLT irradiation dose safely improved the animal outcome, we increased the LLLT power settings and reduced the treatment times for the triple TLT treatment experiments. The change of the setting for the triple dose might be considered as a methodological limitation in our study. However, the decision of changing the settings and irradiation times was made to obtain a more robust response of the multiple laser treatments. Yet, our study was not designed to define the maximal optimal dose of radiation or the total energy tolerated by the ischemic brain. Neither did we set out to determine the specific number of treatments at specific treatment times that could result in optimal behavioral outcomes. This work is currently planned.
Based on the preliminary data from animal studies and the successful NEST 1 and 2 studies, the current phase III clinical trial of TLT, NEST-3, uses a single dose of TLT of approximately 10 mW/cm 2 . Based on our results, higher irradiation settings and multiple treatments could be safely applied to humans during acute ischemia leading to further clinical improvement. To move forward to new clinical trials, our studies need to be replicated, and the questions raised above have to be addressed in future animal studies.
Conclusions
In the present study, incremental treatments with TLT significantly improve behavioral outcome in this stroke animal model. Further studies are needed to improve TLT treatment times, irradiation, and energy levels for optimal human acute ischemic stroke TLT treatment. 
